Retatrutide FDA Approval Timeline — From IND to BLA Submission
A complete chronological timeline of retatrutide's FDA regulatory pathway: IND filing, Phase 1–3 trials, TRIUMPH program results, anticipated Q1 2027 BLA submission, and what comes next.
Last reviewed:
When will retatrutide be FDA approved?
Eli Lilly has stated it plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027, following positive topline results from five Phase 3 TRIUMPH trials. If submitted on schedule and granted standard review, a PDUFA action date would fall approximately 12 months later — Q1 2028. Priority Review, if granted, could shorten that to roughly 6 months. FDA approval is not guaranteed and the timeline is subject to change.
Key Facts
Full Regulatory Timeline
Each milestone is sourced from peer-reviewed publications, ClinicalTrials.gov records, or official Eli Lilly announcements. Projected milestones are based on standard FDA review timelines and are not guarantees.
Preclinical Development and IND Filing
Eli Lilly scientists identified LY3437943 as a novel triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Preclinical studies in animal models demonstrated substantial weight reduction and metabolic improvements. Lilly filed an Investigational New Drug (IND) application with the FDA, which allowed human trials to begin.
Source: Eli Lilly pipeline disclosures ↗Phase 1 — First-in-Human Safety and Pharmacokinetics
The first-in-human Phase 1 trial enrolled healthy volunteers and participants with type 2 diabetes to assess safety, tolerability, and pharmacokinetics across single and multiple ascending doses. The trial established the drug's half-life (approximately 6 days, supporting once-weekly dosing), confirmed dose-dependent GLP-1 and glucagon receptor engagement, and identified the gastrointestinal adverse event profile consistent with other incretin-based therapies. No unexpected safety signals halted development.
Source: ClinicalTrials.gov — LY3437943 Phase 1 ↗Phase 2 — Dose-Finding in Obesity and Type 2 Diabetes
The pivotal Phase 2 trial (NCT04881760) enrolled 338 adults with obesity or overweight and type 2 diabetes across multiple dose cohorts (1 mg, 4 mg, 8 mg, 12 mg) over 48 weeks. Results published in the New England Journal of Medicine (Jastreboff et al., 2023) showed mean body weight reductions of up to 24.2% at the 12 mg dose — the largest weight loss reported for any pharmacotherapy in a Phase 2 trial at that time. A separate Phase 2 MASH trial also demonstrated histological improvement in non-alcoholic steatohepatitis. These results supported advancement to Phase 3.
Source: Jastreboff et al., NEJM 2023 ↗Phase 3 — The TRIUMPH Clinical Program
Lilly launched the TRIUMPH Phase 3 program — a series of large randomized controlled trials across multiple populations. The program includes TRIUMPH-1 (obesity, no T2D), TRIUMPH-2 (obesity + T2D), TRIUMPH-3 (obesity + established CVD), TRIUMPH-CKD (chronic kidney disease), TRIUMPH-MASH (metabolic-associated steatohepatitis), TRIUMPH-Outcomes (cardiovascular outcomes), TRIUMPH-Adolescent, and TRIUMPH-Maintenance. Each trial is registered on ClinicalTrials.gov.
Source: ClinicalTrials.gov — TRIUMPH program ↗TRIUMPH-1 — Positive Topline Results (Obesity, No T2D)
TRIUMPH-1 (NCT05929066) enrolled adults with obesity or overweight without type 2 diabetes. Topline results reported mean body weight reductions of 28.3% at the highest dose (12 mg) at 80 weeks — the largest weight loss reported in a Phase 3 obesity trial to date. The trial met its primary endpoint. Peer-reviewed publication is pending.
Source: Eli Lilly topline announcement ↗TRIUMPH-2 — Positive Topline Results (Obesity + T2D)
TRIUMPH-2 enrolled adults with obesity or overweight and type 2 diabetes. Topline results announced July 23, 2026 showed mean body weight reductions of up to 20.8% at 80 weeks. The trial met its primary endpoint. This result is notable because weight loss in patients with T2D is typically lower than in non-diabetic populations due to the metabolic effects of diabetes medications.
Source: Eli Lilly press release, July 23, 2026 ↗TRIUMPH-3 — Positive Topline Results (Obesity + CVD)
TRIUMPH-3 enrolled adults with severe obesity and established cardiovascular disease. Topline results announced July 23, 2026 showed mean body weight reductions of up to 22.6% at 80 weeks. The trial met its primary endpoint. Cardiovascular outcomes data from TRIUMPH-Outcomes is ongoing and will be required to support labeling claims related to CV risk reduction.
Source: Eli Lilly press release, July 23, 2026 ↗BLA Preparation and Planned Q1 2027 Submission
Following five positive Phase 3 studies, Eli Lilly announced on July 23, 2026 that it has the clinical data package needed to support global regulatory submissions for obesity, knee osteoarthritis pain, and obstructive sleep apnea. Lilly stated it plans to submit a regulatory application to the FDA in Q1 2027. A Biologics License Application (BLA) — not a New Drug Application (NDA) — is the appropriate pathway for a peptide biologic. The BLA package will include all Phase 3 efficacy and safety data, manufacturing information, and proposed labeling.
Source: Eli Lilly press release, July 23, 2026 ↗FDA BLA Review — Standard or Priority Review
Once the BLA is submitted, the FDA has 60 days to accept or refuse to file it. If accepted, the FDA assigns a PDUFA (Prescription Drug User Fee Act) action date — the target date for completing its review. Standard review takes approximately 12 months from acceptance. Priority Review, which the FDA may grant for drugs that offer substantial improvement over available therapies, takes approximately 6 months. Retatrutide may qualify for Priority Review given the magnitude of weight loss observed in trials, but this is not guaranteed. The FDA may also convene an advisory committee to evaluate the benefit-risk profile.
Source: FDA PDUFA process ↗Potential FDA Approval — Estimated Q1 2028 (Standard) or Q3 2027 (Priority)
If the BLA is submitted in Q1 2027 and accepted for standard review, the PDUFA action date would fall approximately Q1 2028. If Priority Review is granted, the action date could be as early as Q3 2027. FDA approval is not guaranteed. The agency may request additional data, issue a Complete Response Letter (CRL) requesting changes, or approve with labeling restrictions. Post-approval, Lilly would need to complete manufacturing scale-up and distribution before the drug is commercially available.
Source: Based on standard FDA review timelines ↗Frequently Asked Questions
Has Eli Lilly submitted the BLA for retatrutide?
As of September 22, 2026, Eli Lilly has not yet submitted the BLA. The company announced on July 23, 2026 that it plans to submit in Q1 2027. Submission has not occurred yet.
What is the difference between a BLA and an NDA for retatrutide?
A New Drug Application (NDA) covers small-molecule drugs. A Biologics License Application (BLA) covers biologic products, including peptides like retatrutide. Because retatrutide is a peptide biologic, Lilly will file a BLA, not an NDA. Some early coverage incorrectly referred to an NDA; the correct term is BLA.
Could retatrutide get Priority Review from the FDA?
Possibly. The FDA grants Priority Review to drugs that offer a significant improvement in safety or effectiveness compared to available therapies. Given the magnitude of weight loss in TRIUMPH trials (up to 28.3% in TRIUMPH-1), retatrutide may qualify. However, Priority Review is not automatic and must be requested and granted by the FDA.
What happens after FDA approval?
After approval, Eli Lilly would need to finalize commercial manufacturing, negotiate pricing with payers, and launch distribution. There is typically a gap of several months between FDA approval and broad commercial availability. Post-marketing commitments, including the ongoing TRIUMPH-Outcomes cardiovascular outcomes trial, would continue.
Is retatrutide available now through compounding pharmacies?
No. Retatrutide has never been FDA approved and has never appeared on the FDA's drug shortage list. It therefore does not qualify for compounding under 503A or 503B pathways. Any product sold as 'retatrutide' by a compounding pharmacy or online vendor is not legally authorized and has not been evaluated for safety or efficacy by the FDA.
How does the retatrutide approval timeline compare to tirzepatide?
Tirzepatide (Mounjaro) received FDA approval for type 2 diabetes in May 2022 and for obesity (Zepbound) in November 2023. Retatrutide is approximately 2–3 years behind tirzepatide in the regulatory process. If approved on the projected timeline, retatrutide would reach the market roughly 4–5 years after tirzepatide's diabetes approval.
Want a Physician to Review Your Eligibility?
Retatrutide is not yet FDA approved. A physician can review your health profile and discuss investigational access options or clinical trial enrollment.
Start Physician Review